An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Clinical trial NCT02657343 · COMPLETED
Trial details
- NCT number
- NCT02657343
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-09
- Primary completion
- 2020-08-27
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.